TuScreen Included on Vietnamese MOH Approved Technical List

NZX/ASX Announcement

13 December 2023

TruScreen included on the Vietnamese Ministry Of Health Approved Technical List

Highlights:

• TruScreen included on the Vietnamese Ministry of Health approved Technical List
• The Technical Listing will simplify and shorten the procurement process for public
hospitals.
• The Technical Listing will enable nationwide adoption of TruScreen in the public
healthcare sector.

TruScreen Group Limited (NZX/ASX:TRU) is pleased to advise that it has been included in the
Vietnamese Ministry Of Health (MOH) approved Technical List. This significant milestone enables
TruScreen to be used nationally from top level hospitals to community health centres. The listing
reduces the need for individual hospitals to seek prior approval thereby shortening dramatically the
procurement process.
The MOH recognised the value of the Truescreen technology in accelerating the cervical cancer
screening at lower public healthcare costs with greater innovative patient-focused approach. The
listing by the MOH was based on extensive clinical evidence supporting TruScreen, positive feedback
from local users at several levels of the public healthcare providers, including leading gynaecological
hospital, Hanoi Obstetrics and Gynaecology Hospital.
The Inclusion in the approved Technical List will allow our distributor Gorton Health Services (GHS)
to expand distribution of the TruScreen AI-enable technology in Vietnam.
CEO, Dr Beata Edling said:
“We are delighted that the Ministry of Health in Vietnam has approved TruScreen as the technology
that will assist Vietnam in achieving the World Health Organisation targets in cervical cancer
screening. The work of our partner in Vietnam, GHS, has prepared Truscreen for an accelerated
national uptake. We congratulate GHS on their efforts and look forward to this new phase of growth
development”.

This announcement has been approved by the Board.
Ends

For more information, visit www.truscreen.com or contact:

Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com





About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and
manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via
measurements of the low level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and
processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly,
specialised personnel and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is registered as a primary screening device for cervical
cancer screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the
TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and
COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the
Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a
manufacturing facility in China for devices marketed and sold in China.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy and
Cervical Pathology) China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage Standardized
Prevent and Treatment” published on 28 April 2023.
In financial year 2023 alone, over 140000* examinations have been performed
with TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam,
Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen’s vision is “A world without the cervical
cancer”
©
.
To learn more, please visit: www.truscreen.com/.
*Based on Single Use Sensor sales.

Glossary:
Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the
cervix, with a special brush. The sample is placed on a glass slide or in a bottle containing a solution to
preserve the cells. Then it is sent to a laboratory for a pathologist to examine under a
microscope. https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-procedures/pap-
test
LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix,
onto a slide after removing blood or mucus from the sample. The sample is preserved so other tests can be
done at the same time, such as the human papillomavirus (HPV) test https://www.cancer.net/cancer-
types/cervical-cancer/diagnosis

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same sample
used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked to cervical
cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test may also be
done on a sample of cells which a person can collect on their own.
https://www.cancer.net/cancer-
types/cervical-cancer/screening-and-prevention

Sensitivity and specificity mathematically describe the accuracy of a test which reports the presence
or absence of a condition. If individuals who have the condition are considered "positive" and those who
don't are considered "negative", then sensitivity is a measure of how well a test can identify true positives
and specificity is a measure of how well a test can identify true negatives:
• Sensitivity (true positive rate) is the probability of a positive test result, conditioned on the
individual truly being positive.
• Specificity (true negative rate) is the probability of a negative test result, conditioned on the
individual truly being negative (Sensitivity and specificity – Wikipedia).
For more information about the cervical cancer and cervical cancer screening in New Zealand and Australia,
please see useful links:
New Zealand: National Cervical Screening Programme | National Screening Unit (nsu.govt.nz)

Australia: Cervical cancer | Causes, Symptoms & Treatments | Cancer Council